Statement of Principles

Two thirds of all deaths worldwide, and about 90% of all deaths in the developed world, are from causes that only rarely kill young adults. These causes include Alzheimer's, cardiovascular disease, Type II diabetes and most cancers. They are age-related because they are expressions of the later stages of aging, occurring when the molecular and cellular damage that has accumulated in the body throughout life exceeds the level that metabolism can tolerate. Moreover, before it kills them, aging imposes on most elderly people a long period of debilitation and disease. For these reasons, aging is unarguably the most prevalent medically-relevant phenomenon in the modern world and the primary ultimate target of biomedical research.

Regenerative medicine can be defined as the restoration of an individual's molecular, cellular and/or tissue structure to broadly the state it was in before it experienced damage or degeneration. Aging is a degenerative process, so in theory it can be treated by regenerative medicine, thereby postponing the entire spectrum of age-related frailty and disease. But in practice, could regenerative medicine substantially postpone aging any time soon? If so, it will do so via the combined application of many distinct regenerative therapies, since aging affects the body in so many ways. Recent biotechnological progress indicates that many aspects of aging may indeed be effectively treatable by regenerative medicine in the foreseeable future. We cannot yet know whether all aspects will be, but extensive scrutiny has failed to identify any definite exceptions. Therefore, at this point there is a significant chance that such therapies would postpone age-related decline by several years, if not more, which constitutes a clear case for allocating significant resources to the attempt to develop those therapies.

Unfortunately, the regenerative medicine approach to combating aging is not yet being adequately pursued by major funding bodies: only a small number of laboratories worldwide are funded (either publicly or privately) to develop therapies that could rejuvenate aged but otherwise undamaged tissues. SENS Foundation has risen to the challenge of filling this void in the biomedical research funding arena. Research is chosen for funding by SENS Foundation on the basis of the following major criteria:

• It is demonstrably relevant to the development of regenerative medicine targeting some aspect of aging.
• It is poorly funded by other sources.
• Funding from other sources seems unlikely to be forthcoming in the near future.

As and when it is developed, this panel of therapies may provide many years, even decades, of additional youthful life to countless millions of people. Those extra years will be free of all age-related diseases, as well as the frailty and susceptibility to infections and falls that the elderly also experience. The alleviation of suffering that will result, and the resulting economic benefits of maintained productivity of the population, are almost incalculable. In our capacity as the overseers of SENS Foundation's research strategy, we urge you to do all you can to help SENS Foundation carry out this mission with maximum speed.

Signed,

	Pedro Alvarez, PhD George R. Brown Professor of Engineering, Rice University
	Anthony Atala, MD Director, Wake Forest Institute for Regenerative Medicine
	María A. Blasco, PhD Director, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO)
	Judith Campisi, PhD Senior Scientist, Buck Institute for Age Research
	Irina Conboy, PhD Assistant Professor, Department of Bioengineering, UC Berkeley, and Berkeley Stem Cell Center
	Marisol Corral-Debrinski, PhD Research Director, Fondation Voir et Entendre, Institut de la Vision, Universite Pierre et Marie Curie
	Leonid Gavrilov, PhD Research Associate, Center on Aging, NORC and the University of Chicago
	S. Mitchell Harman, PhD Director and President of Kronos Longevity Research Institute
	William Haseltine, PhD Chair, Haseltine Global Health
	Daniel Kraft, MD Stanford Institute for Stem Cell Biology and Regenerative Medicine
	Chris Mason, PhD Chair of Regenerative Medicine Bioprocessing, University College London
	Stephen Minger, PhD Global Director of R&D, Cell Technologies, GE Healthcare
	Janko Nikolich-Zugich, MD, PhD Chair, Department of Immunobiology and Co-director, Center on Aging, University of Arizona
	Graham Pawelec, PhD Professor of Experimental Immunology, Tübingen University
	Bruce Rittmann, PhD Director, Institute for Environmental Biotechnology, Biodesign Institute, Arizona State University
	Nadia Rosenthal, PhD Scientific Director, National Heart & Lung Institute, Imperial College London
	Jerry Shay, PhD Vice-Chairman, Department of Cell Biology, University of Texas Southwestern Medical Center
	Vladimir Skulachev, ScD Head, Department of Bioenergetics, A.N. Belozersky Institute of Physico-Chemical Biology
	David Spiegel, PhD Assistant Professor of Chemistry, Yale University
	Alexandra Stolzing, PhD Group Leader, Stem Cell Biology and Regeneration, Fraunhofer Institute
	Rudolph Tanzi, PhD Joseph P. and Rose F. Kennedy Professor of Child Neurology and Mental Retardation, Harvard University
	Fyodor Urnov, PhD Head, Advanced Genomics Technologies, Sangamo Biosciences; Adjunct Professor, UC Berkeley
	Jan Vijg, PhD Chair, Department of Genetics, Albert Einstein College of Medicine
	Michael West, PhD CEO, Biotime Inc.